<DOC>
	<DOCNO>NCT01380184</DOCNO>
	<brief_summary>Part 1 study ass pharmacokinetics , safety , tolerability ridaforolimus administration single multiple 40 mg dos Chinese participant advance cancer . Part 2 study optional ; participant continue receive study drug weekly regimen daily oral dos ridaforolimus 40 mg 5 consecutive day follow 2 day off-drug .</brief_summary>
	<brief_title>Pharmacokinetics Ridaforolimus Chinese Participants ( MK-8669-059 )</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Chinese descent 4 biological grandparent bear China Chinese descent . Histologically cytologicallyconfirmed metastatic locally advanced solid tumor lymphoma fail respond standard therapy , progress despite standard therapy , standard therapy exist . Performance status â‰¤1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Female participant must postmenopausal . Male participant must agree use medicallyacceptable method contraception/barrier protection study 30 day last dose study drug . Participants must healthy enough receive study drug ( , meet certain laboratory value parameter ) . Life expectancy &gt; 3 month . Exclusion criterion : Chemotherapy , radiotherapy , biological therapy within 4 week ( 6 week nitrosoureas , mitomycin C , monoclonal antibody ) prior first dose study drug ( Part 1/Day 1 ) recover adverse event due agent administer 4 week earlier . Any concurrent anticancer therapy ( except luteinizing hormone release hormone [ LHRH ] analog prostate cancer ) . Concurrent treatment immunosuppressive agent , include corticosteroid , dos great use replacement therapy . Clinically significant abnormality electrocardiogram ( ECG ) perform screen visit and/or prior administration initial dose study drug . New York Heart Association ( NYHA ) Class III IV congestive heart failure significant history cardiac disease include : myocardial infarction within last 6 month ; ventricular arrhythmia acute congestive heart failure within last 3 month ; uncontrolled angina ; uncontrolled hypertension . Current participation participation study investigational compound device within 30 day prior first dose study drug . Primary central nervous system tumor , active brain metastasis leptomeningeal carcinomatosis . Regular use ( include use illicit drug recent history within last year ) drug , alcohol abuse . Pregnant breastfeeding , expect conceive within project duration study . Human Immunodeficiency Virus ( HIV ) positive . Newly diagnose ( within 3 month first dose study drug ) poorly control Type 1 2 diabetes . Required treatment medication inducer inhibitor cytochrome P450 ( CYP3A ) . Active infection use intravenous ( IV ) antibiotic , antiviral , antifungal agent within 2 week prior first dose study drug . Use intention use herbal tea herbal remedy ( include traditional Chinese medicine , St. John 's Wort , shark cartilage , etc . ) 2 week prior first dose throughout study . Anticipation need immunologic therapy , radiation therapy , surgery , chemotherapy study . Past highdose chemotherapy stem cell rescue . Blood transfusion within one week study entry . Inability swallow capsule and/or document surgical anatomical condition preclude swallow absorb oral medication ongoing basis . Known hypersensitivity component study drug analog antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) . Intention consume grapefruit grapefruit juice approximately 2 week prior first dose completion study . Inadequate recovery prior surgical procedure major surgical procedure within 4 week prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Relapsed cancer</keyword>
</DOC>